Skip to main content
Funded Studies

Stephanos Ioannidis, PhD

Director of Medicinal Chemistry at FORMA Therapeutics

Location: Watertown, MA United States

Dr. Stephanos Ioannidis obtained his bachelor of science at King's College London in chemistry and biochemistry. He then moved to the Imperial College London where he received his PhD in organic chemistry under the supervision of Professor Donald Craig. Following his PhD work, Dr. Stephanos joined the laboratory of Professor Yoshito Kishi at Harvard University as post-doctoral fellow. After completing his post-doctoral studies, he joined AstraZeneca in Waltham, MA. At AstraZeneca, he led several drug discovery teams from target validation stages to the clinic.

In 2013, after more than 11 years of a successful career at AstraZeneca, Dr. Stephanos moved to FORMA Therapeutics in Watertown, MA. At FORMA Therapeutics, Dr. Ioannidis leads the protein homeostasis area where one of his responsibilities includes the discovery of novel small molecules of deubiquitinase (type of enzyme; DUB) enzymes. Other responsibilities include leadership of early discovery and, more recentl,y leading DUB projects related to Parkinson's disease.

Associated Grants

  • Developing New Drugs that Deactivate Deubiquitinase Proteins for the Treatment of Parkinson's Disease


  • Protein Homeostasis and the Ubiquitination Pathway in Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.